Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Blood Rev. 2017 Oct 3;32(2):130–143. doi: 10.1016/j.blre.2017.10.001

Figure 5. Novel treatments for β-thalassemia.

Figure 5

Current management of β-thalassemia with RBC transfusions and iron chelation does not efficiently address the pathophysiology of IE. As described in the text, novel drugs are being developed to target proteins that modulate erythropoiesis, iron metabolism or the activity of some of the ligands of the TGF-β superfamily. These molecules have the potential to improve the phenotype of the disease and reduce the risk of complications.